Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina
- PMID: 10349897
- DOI: 10.1001/jama.281.20.1927
Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina
Abstract
Context: Which drug is most effective as a first-line treatment for stable angina is not known.
Objective: To compare the relative efficacy and tolerability of treatment with beta-blockers, calcium antagonists, and long-acting nitrates for patients who have stable angina.
Data sources: We identified English-language studies published between 1966 and 1997 by searching the MEDLINE and EMBASE databases and reviewing the bibliographies of identified articles to locate additional relevant studies.
Study selection: Randomized or crossover studies comparing antianginal drugs from 2 or 3 different classes (beta-blockers, calcium antagonists, and long-acting nitrates) lasting at least 1 week were reviewed. Studies were selected if they reported at least 1 of the following outcomes: cardiac death, myocardial infarction, study withdrawal due to adverse events, angina frequency, nitroglycerin use, or exercise duration. Ninety (63%) of 143 identified studies met the inclusion criteria.
Data extraction: Two independent reviewers extracted data from selected articles, settling any differences by consensus. Outcome data were extracted a third time by 1 of the investigators. We combined results using odds ratios (ORs) for discrete data and mean differences for continuous data. Studies of calcium antagonists were grouped by duration and type of drug (nifedipine vs nonnifedipine).
Data synthesis: Rates of cardiac death and myocardial infarction were not significantly different for treatment with beta-blockers vs calcium antagonists (OR, 0.97; 95% confidence interval [CI], 0.67-1.38; P = .79). There were 0.31 (95% CI, 0.00-0.62; P = .05) fewer episodes of angina per week with beta-blockers than with calcium antagonists. beta-Blockers were discontinued because of adverse events less often than were calcium antagonists (OR, 0.72; 95% CI, 0.60-0.86; P<.001). The differences between beta-blockers and calcium antagonists were most striking for nifedipine (OR for adverse events with beta-blockers vs nifedipine, 0.60; 95% CI, 0.47-0.77). Too few trials compared nitrates with calcium antagonists or beta-blockers to draw firm conclusions about relative efficacy.
Conclusions: beta-Blockers provide similar clinical outcomes and are associated with fewer adverse events than calcium antagonists in randomized trials of patients who have stable angina.
Comment in
- ACP J Club. 1999 Nov-Dec;131(3):62
Similar articles
-
[Systematic review on the short-term efficacy and safety of nicorandil for stable angina pectoris in comparison with those of β-blockers, nitrates and calcium antagonists].Yakugaku Zasshi. 2010 Nov;130(11):1549-63. doi: 10.1248/yakushi.130.1549. Yakugaku Zasshi. 2010. PMID: 21048416 Japanese.
-
Choosing the most appropriate treatment for stable angina. Safety considerations.Drug Saf. 1998 Jul;19(1):23-44. doi: 10.2165/00002018-199819010-00003. Drug Saf. 1998. PMID: 9673856 Review.
-
Safety of nifedipine in angina pectoris: a meta-analysis.Hypertension. 1999 Jan;33(1):24-31. doi: 10.1161/01.hyp.33.1.24. Hypertension. 1999. PMID: 9931077
-
Calcium channel blocking drugs for chronic, stable angina.Int J Cardiol. 1982;2(1):1-5. doi: 10.1016/0167-5273(82)90002-x. Int J Cardiol. 1982. PMID: 6127320
-
Trimetazidine for stable angina.Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003614. doi: 10.1002/14651858.CD003614.pub2. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2017 Mar 20;3:CD003614. doi: 10.1002/14651858.CD003614.pub3. PMID: 16235330 Updated. Review.
Cited by
-
Sex and gender bias in chronic coronary syndromes research: analysis of studies used to inform the 2019 European Society of Cardiology guidelines.Lancet Reg Health Eur. 2024 Aug 30;45:101041. doi: 10.1016/j.lanepe.2024.101041. eCollection 2024 Oct. Lancet Reg Health Eur. 2024. PMID: 39279866 Free PMC article.
-
Should We Use Aspirin or P2Y12 Inhibitor Monotherapy in Stable Ischemic Heart Disease?Curr Atheroscler Rep. 2024 Nov;26(11):649-658. doi: 10.1007/s11883-024-01234-2. Epub 2024 Sep 7. Curr Atheroscler Rep. 2024. PMID: 39243345 Review.
-
Chronic Coronary Disease in Older Adults.Med Clin North Am. 2024 May;108(3):581-594. doi: 10.1016/j.mcna.2023.12.004. Epub 2024 Jan 4. Med Clin North Am. 2024. PMID: 38548465 Review.
-
Management of Stable Angina in the Older Adult Population.Circ Cardiovasc Interv. 2023 Apr;16(4):e012438. doi: 10.1161/CIRCINTERVENTIONS.122.012438. Epub 2023 Mar 14. Circ Cardiovasc Interv. 2023. PMID: 36916288 Free PMC article. Review.
-
In Vitro Drug Repurposing: Focus on Vasodilators.Cells. 2023 Feb 20;12(4):671. doi: 10.3390/cells12040671. Cells. 2023. PMID: 36831338 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
